SavedAdd your journal

Journals / Endoüroloji Bülteni / 2020 / Cilt: 12 Sayı: 3

Intradetrusor onabotulinumtoxin A injection for the treatment of overactive bladder resistant to medical therapy

Medikal tedaviye dirençli aşırı aktif mesane tedavisinde detrüsör içi botulinum toksin enjeksiyonu

Adem Emrah Coğuplugil(Gülhane Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye)0000-0002-6240-4989
Bahadır Topuz(Gülhane Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye)0000-0001-6209-803X
Sercan Yilmaz(Gülhane Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye)0000-0001-6820-6708
Murat Zor(Gülhane Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye)0000-0003-2597-5026
Mesut Gürdal(Gülhane Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara, Türkiye)0000-0002-2535-8506
Pages
187–191
Publication Date
2020-12-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Intradetrusor injection of 100 U BONTA continues to be used as an effective and safe treatment method in patients with resistant OAB.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives : To present the results of onabotulinumtoxin-A (BONTA) injections in patients with overactive bladder (OAB) resistant to medical therapy.
📊
Key Findings & Data:Material and Methods : Patients who underwent BONTA injection due to resistant OAB between 2013-2018 were included in this retrospective study.
💡
Conclusion & Impact:Conclusion: Intradetrusor injection of 100 U BONTA continues to be used as an effective and safe treatment method in patients with resistant OAB.
🔬Design:Araştırma Makalesi
📍Scope:2013-2018 Verileri
⚙️Variables:aşırı aktif mesane · dirençli · detrüsör içi onabotulinum toksinA enjeksiyonu

Abstract

Objectives : To present the results of onabotulinumtoxin-A (BONTA) injections in patients with overactive bladder (OAB) resistant to medical therapy. Material and Methods : Patients who underwent BONTA injection due to resistant OAB between 2013-2018 were included in this retrospective study. Patients who have used at least two different antimuscarinic drugs for 3 months and not improved or cannot tolerate side effects are identified as resistant OAB. The diagnosis of OAB was made by urodynamic study and/or by clinical findings. All patients were evaluated with urinalysis and urine culture, post-void residual urine measurement (PVR) and voiding diary, and/or symptom scores preoperatively and postoperatively at 2 weeks, 3 months and 6 months. Improvement was determined as continence or> 50% improvement in symptoms. All side effects were recorded. Results: 71 resistant OAB patients underwent intradetrusor 100 U BONTA injection. Mean patient age was 33,5 years (range:21-86). Improvement rates were 78,8% at 3 months and 67,6% at 6 months. Complications were as follows; clean intermittent catheterization (CIC) due to high PVR (12,6%), microscopic transient hematuria (7,1%), and acute cystitis (8,4%). High PVR values returned to normal within 5 weeks in all patients who underwent CIC. Systemic side effects or acute urinary retention did not occur. Conclusion: Intradetrusor injection of 100 U BONTA continues to be used as an effective and safe treatment method in patients with resistant OAB.

Özet

Giriş : Bu çalışmada dirençli aşırı aktif mesane (AAM) hastalarında onabotulinumtoksin-A (BONTA) enjeksiyonu sonuçları sunulmaktadır. Gereç ve Yöntemler: 2013-2018 yıllarında dirençli AAM nedeniyle BONTA uygulanan hastalar retrospektif olarak taranıp kaydedildi. En az iki antimuskarinik ilacı 3 ay süreyle kullanmış olmasına rağmen fayda görmeyen ya da yan etkilerini tolere edemeyen hastalar dirençli AAM olarak tanımlandı. Hastalara ürodinamik ve/veya klinik olarak AAM tanısı kondu. Preoperatif ve postoperatif 2 hafta, 3 ay ve 6 ayda idrar analizi ve kültürü, postvoid rezidü idrar (PVR) ölçümü ve işeme günlüğü ve /veya semptom skorları ile değerlendirme yapıldı. İyileşme, tam kuruluk sağlanması veya semptomlarda >%50 düzelme olarak belirlendi. Tüm yan etkiler kaydedildi. Bulgular: 71 hastaya dirençli AAM tanısıyla detrüsör içi 100 Ü BONTA uygulandı. Ortalama hasta yaşı 33.5 idi (aralık: 21-86 yıl). İyileşme oranları üçüncü ayda %78.8 ve altıncı ayda %67.6 idi. Komplikasyonlar şu şekildeydi; yüksek PVR nedeniyle temiz aralıklı kateterizasyon (TAK, %12.6), mikroskobik geçici hematüri (%7.1) ve üriner enfeksiyon (%8.4). TAK başlanan hastaların tümünde 5 hafta içinde yüksek PVR değerleri normale döndü. Akut retansiyon ve sistemik yan etki görülmedi. Sonuç : Dirençli AAM hastalarında detrüsör içi 100 Ü BONTA enjeksiyonu etkili ve düşük komplikasyon oranları ile güvenli bir yöntem olarak kullanılmaya devam etmektedir.

🔖

Cite This Article

Coğuplugil, A. E., Topuz, B., Yilmaz, S., Zor, M., Gürdal, M. (2020). Intradetrusor onabotulinumtoxin A injection for the treatment of overactive bladder resistant to medical therapy. Endoüroloji Bülteni, Cilt: 12 Sayı: 3, 187–191. https://ajindex.com/articles/1479111

References (12)

  1. Referans1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167‐178.
  2. Referans2. Gormley EA, Lightner DJ, Faraday M, Vasavada SP; American Urological Association; Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572‐1580.
  3. Referans 3. Phé V, de Wachter S, Rouprêt M, Chartier-Kastler E. How to define a refractory idiopathic overactive bladder? Neurourol Urodyn. 2015;34(1):2‐11.
  4. Referans4. Nambiar AK, Bosch R, Cruz F, et al. EAU Guidelines on Assessment and Non-surgical Management of Urinary Incontinence. Eur Urol. 2018;73(4):596‐609.
  5. Referans5. Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186‐2193.
  6. Referans. Onem K, Bayrak O, Demirtas A, et al. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in T Turkish population. Neurourol Urodyn. 2018;37(1):263‐268.
  7. Referans7. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416‐2422.
  8. Referans8. Chermansky CJ, Chancellor MB. Use of Botulinum Toxin in Urologic Diseases. Urology. 2016;91:21‐32.
  9. Referans9. Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol. 2012;62(3):507‐514.
  10. Referans10. Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?. Urology. 2006;68(5):993‐998.
  11. Referans11. Jiang YH, Ong HL, Kuo HC. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center. Neurourol Urodyn. 2017;36(1):142‐147.
  12. Referans. Onem K, Bayrak O, Demirtas A, et al. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in T Turkish population. Neurourol Urodyn. 2018;37(1):263‐268.